JP2020500922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500922A5 JP2020500922A5 JP2019531255A JP2019531255A JP2020500922A5 JP 2020500922 A5 JP2020500922 A5 JP 2020500922A5 JP 2019531255 A JP2019531255 A JP 2019531255A JP 2019531255 A JP2019531255 A JP 2019531255A JP 2020500922 A5 JP2020500922 A5 JP 2020500922A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- dose
- antitumor
- human interleukin
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 44
- 229940127089 cytotoxic agent Drugs 0.000 claims 26
- 230000002238 attenuated effect Effects 0.000 claims 14
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 12
- 102000055277 human IL2 Human genes 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000013612 plasmid Substances 0.000 claims 9
- 108091026890 Coding region Proteins 0.000 claims 8
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 241001529936 Murinae Species 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229940041181 antineoplastic drug Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000001988 toxicity Effects 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 241001467018 Typhis Species 0.000 claims 3
- 208000037386 Typhoid Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000008297 typhoid fever Diseases 0.000 claims 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143644A JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430962P | 2016-12-07 | 2016-12-07 | |
| US62/430,962 | 2016-12-07 | ||
| PCT/US2017/064813 WO2018106754A1 (en) | 2016-12-07 | 2017-12-06 | Methods of synergistic treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143644A Division JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500922A JP2020500922A (ja) | 2020-01-16 |
| JP2020500922A5 true JP2020500922A5 (enExample) | 2021-01-28 |
| JP7249279B2 JP7249279B2 (ja) | 2023-03-30 |
Family
ID=62492129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531255A Active JP7249279B2 (ja) | 2016-12-07 | 2017-12-06 | がんの相乗的治療方法 |
| JP2022143644A Pending JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143644A Pending JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11576936B2 (enExample) |
| EP (1) | EP3550976A4 (enExample) |
| JP (2) | JP7249279B2 (enExample) |
| WO (1) | WO2018106754A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106754A1 (en) * | 2016-12-07 | 2018-06-14 | Md Biosciences, Inc. | Methods of synergistic treatment of cancer |
| US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CN118147029A (zh) | 2018-07-11 | 2024-06-07 | 阿克蒂姆治疗有限公司 | 工程化的免疫刺激性细菌菌株及其用途 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| KR20220121245A (ko) * | 2019-12-26 | 2022-08-31 | 살스퍼라, 엘엘씨 | 고형 종양 암의 치료 방법 및 제제 |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
| JP2024542851A (ja) | 2021-12-09 | 2024-11-15 | プロカリウム リミテッド | がんの併用療法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| US6531164B1 (en) | 1998-12-03 | 2003-03-11 | The Crede Family Trust | Enteral pharmaceutical preparation |
| WO2001024637A1 (en) | 1999-10-04 | 2001-04-12 | Vion Pharmaceuticals, Inc. | Methods for treating solid tumors with irradiation and bacteria |
| US20020160502A1 (en) | 2000-09-26 | 2002-10-31 | Roger Williams Hospital | Recombinant BCG vaccines for the prevention and treatment of cancer |
| US20080107758A1 (en) | 2001-06-15 | 2008-05-08 | Cuticeuticals, Inc. | Topical steroid spray with botanic seed oils |
| WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
| DE10208653A1 (de) | 2002-02-28 | 2003-09-18 | Medinnova Ges Med Innovationen | Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren |
| SG179291A1 (en) | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| US20050244375A1 (en) | 2004-04-29 | 2005-11-03 | Leonard Arnold S | Composition and method of cancer treatment |
| US7897194B2 (en) | 2006-04-18 | 2011-03-01 | Botanic Oil Innovations, Inc. | Synergistic super potent antioxidant cold pressed botanic oil blends |
| US8221739B2 (en) * | 2004-04-29 | 2012-07-17 | Botanic Oil Innovations, Inc. | Method of cancer treatment |
| US20070128301A1 (en) | 2005-09-07 | 2007-06-07 | Saltzman Daniel A | Immune enhancement by seed oil and/or seed flour |
| CN101273133A (zh) | 2005-08-30 | 2008-09-24 | 联邦科学工业研究组织 | 生物活性多肽的细菌传送 |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| US9127284B2 (en) | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
| CN105983103B (zh) | 2015-03-17 | 2025-01-07 | 广州华津医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
| WO2018106754A1 (en) | 2016-12-07 | 2018-06-14 | Md Biosciences, Inc. | Methods of synergistic treatment of cancer |
-
2017
- 2017-12-06 WO PCT/US2017/064813 patent/WO2018106754A1/en not_active Ceased
- 2017-12-06 JP JP2019531255A patent/JP7249279B2/ja active Active
- 2017-12-06 US US16/467,338 patent/US11576936B2/en active Active
- 2017-12-06 EP EP17877671.2A patent/EP3550976A4/en active Pending
-
2022
- 2022-09-09 JP JP2022143644A patent/JP2022171776A/ja active Pending
-
2023
- 2023-01-26 US US18/159,934 patent/US12090179B2/en active Active
-
2024
- 2024-08-28 US US18/817,472 patent/US20240415898A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500922A5 (enExample) | ||
| CN1140272C (zh) | 抗肿瘤剂 | |
| Hande et al. | Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer | |
| JP2005008534A (ja) | 抗癌剤及び癌の治療方法 | |
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| KR20180125967A (ko) | 암 치료용 pic 포함 조성물 | |
| KR101245328B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물을 포함하는 항암제 조성물 | |
| CN109528731B (zh) | 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用 | |
| KR101964169B1 (ko) | 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제 | |
| CN101568338A (zh) | 白血病治疗的新治疗用途 | |
| US20160375057A1 (en) | Therapeutic compositions and methods involving cell-permeable iron | |
| CN115227690B (zh) | 土木香内酯在双表达型b细胞淋巴瘤中的应用 | |
| CN106668061B (zh) | 一种含有顺铂的抗癌药物组合物 | |
| CN104146999A (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
| CN114302729B (zh) | 癌化学疗法支持剂及药品 | |
| TWI656131B (zh) | Ｎｒｆ－１蛋白質用以製備治療膀胱癌之藥物的用途 | |
| CN107519171A (zh) | 洛匹那韦减轻伊立替康毒性的医药新用途 | |
| JPH0211513A (ja) | 制癌剤 | |
| CN115581703A (zh) | 复方吉西他滨组合物及应用 | |
| Jin et al. | Grade Ⅳ myelosuppression after induction chemotherapy of TPF on oral cancer: clinical analysis of 29 cases | |
| CN107441088A (zh) | 阿扎那韦减轻伊立替康毒性的医药新用途 | |
| CONPAINING | CHEMOTHERAPY/SMALL CELL 98 | |
| Ameri et al. | Vinorelbine and docetaxel combination as the first line treatment in patients with metastatic breast cancer: results of a multi-centric phase ii trial in Iran |